The dramatic disruption of proangiogenic and tumor progression programs and the overcoming the immunosuppressive TME, attributed to the selective nanoliposome-mediated deletion of the IL30 gene in cancer cells, paves the way for the development of a modern and safe immuno-nanotherapy for advanced PC that meets the needs of healthy aging. This evidence concerns the gene IL27 and cancer.